Under construction – not a live service
Sign in
Taking peoplePhase 4

Long-term safety follow-up of people treated with cilta-cel for multiple myeloma

Follows adults with multiple myeloma previously treated with cilta-cel to study late side effects.

Plain-language title generated from the registry record
Registry title: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Key facts

Where
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, and Xi'an, ChinaSee the 11 sites
Phase
Phase 4

Where in China

  • Peking University Third HospitalBeijing, ChinaNo longer taking part
  • West China Hospital Si Chuan UniversityChengdu, ChinaNo longer taking part
  • Fujian Medical University Union HospitalFuzhou, ChinaNo longer taking part
  • Sun Yat-sen University Cancer HospitalGuangzhou, ChinaNo longer taking part
  • First Hospital, Zhejiang University Medical CollegeHangzhou, ChinaNo longer taking part
  • Jiangsu Province HospitalNanjing, ChinaNo longer taking part
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaNo longer taking part
  • Ruijin Hospital Shanghai Jiao Tong UniversityShanghai, ChinaNo longer taking part
  • Shanghai Changzheng HospitalShanghai, ChinaNo longer taking part
  • Shanghai Fourth People's HospitalShanghai, ChinaNo longer taking part
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Janssen Research & Development, LLC
Trial code
NCT05201781EU 2023-505530-10-00
Record updated
3 November 2026
Original description
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.Read full original descriptionShow less

Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Inclusion: Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study; Participants who have provided informed consent for this study.

ClinicalTrials.gov NCT05201781 · EU CTIS 2023-505530-10-00

Under construction, not live – A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel (NCT05201781) – Frontlight Research